Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2025 08:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series

OCALA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will...
November 27, 2025 08:20 ET | Source: Research and Markets

Her3-Targeted Immunotherapies Pipeline and Competitive Intelligence Report

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of Her3-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
November 27, 2025 08:16 ET | Source: Research and Markets

Mesothelin-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of Mesothelin-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
November 10, 2025 13:30 ET | Source: Imunon, Inc.

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

Webcast Recording and Symposium Slides Now Available LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its...
November 10, 2025 09:37 ET | Source: Research and Markets

India $91.28 Mn Chemotherapy at Home Service Market Analysis, Competition, Opportunities & Forecasts, 2030F

Dublin, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The "India Chemotherapy at Home Service Market, By Region, By Competition, Opportunities & Forecast, 2020-2030F" has been added to ...
November 10, 2025 08:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today detailed a recent abstract containing data from the completed Phase 2 advanced...
November 05, 2025 04:06 ET | Source: Research and Markets

Oncology Adjuvants Research Report 2025: Market to Reach $2.17 Billion by 2029, Driven by Precision-, Immuno-Oncology, AI-Driven Models and Nanotechnology-Enhanced Adjuvants - Forecast to 2034

Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Oncology Adjuvants Market Report 2025" report has been added to ResearchAndMarkets.com's offering.The oncology adjuvants market size has grown...
November 04, 2025 09:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced...
October 21, 2025 10:24 ET | Source: Step Pharma

Step Pharma to spotlight work in CTPS2-null solid tumours at 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

Saint-Genis-Pouilly, France, 21 October 2025 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces that its Chief Scientific Officer,...
October 21, 2025 03:00 ET | Source: Step Pharma

Step Pharma to spotlight work in CTPS2-null solid tumours at 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

Saint-Genis-Pouilly, France, 21 October 2025 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces that its Chief Scientific Officer,...